Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of monocitary subpopulations in relation to cardiovascular risk factors.
Marcos Jubilar M, Orbe J, Roncal C, Fernández Montero A, Colina I, Rodil R, Rodriguez JA, Zabaleta A, Paiva B, Pastrana JC, Páramo JA. Marcos Jubilar M, et al. Among authors: zabaleta a. Clin Investig Arterioscler. 2019 Jul-Aug;31(4):152-159. doi: 10.1016/j.arteri.2019.02.003. Epub 2019 Apr 6. Clin Investig Arterioscler. 2019. PMID: 30967277 English, Spanish.
Immunophenotypic Pattern of De Novo Malignancy After Liver Transplantation.
González JP, Zabaleta A, Sangro P, Basualdo JE, Burgos L, Paiva B, Herrero JI. González JP, et al. Among authors: zabaleta a. Transplant Proc. 2019 Jan-Feb;51(1):77-79. doi: 10.1016/j.transproceed.2018.04.090. Epub 2019 Jan 14. Transplant Proc. 2019. PMID: 30655139
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B. Moreno L, et al. Among authors: zabaleta a. Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28. Clin Cancer Res. 2019. PMID: 30692097
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, Alameda D, San José-Eneriz E, Merino J, Rodríguez-Otero P, Maia C, Alignani D, Maiso P, Manrique I, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Riillo C, Rossi M, Rosiñol L, Oriol A, Blanchard MJ, Rios R, Sureda A, Martin J, Martinez R, Bargay J, de la Rubia J, Hernandez MT, Martinez-Lopez J, Orfao A, Agirre X, Prosper F, Mateos MV, Lahuerta JJ, Blade J, San-Miguel JF, Paiva B. Perez C, et al. Among authors: zabaleta a. Blood. 2020 Jul 9;136(2):199-209. doi: 10.1182/blood.2019004537. Blood. 2020. PMID: 32325491 Free article. Clinical Trial.
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients.
Martín-Sánchez E, Garcés JJ, Maia C, Inogés S, López-Díaz de Cerio A, Carmona-Torre F, Marin-Oto M, Alegre F, Molano E, Fernandez-Alonso M, Perez C, Botta C, Zabaleta A, Alcaide AB, Landecho MF, Rua M, Pérez-Warnisher T, Blanco L, Sarvide S, Vilas-Zornoza A, Alignani D, Moreno C, Pineda I, Sogbe M, Argemi J, Paiva B, Yuste JR. Martín-Sánchez E, et al. Among authors: zabaleta a. Front Immunol. 2021 May 3;12:659018. doi: 10.3389/fimmu.2021.659018. eCollection 2021. Front Immunol. 2021. PMID: 34012444 Free PMC article.
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.
Tamariz-Amador LE, Battaglia AM, Maia C, Zherniakova A, Guerrero C, Zabaleta A, Burgos L, Botta C, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oiartzabal I, Panizo C, Prosper F, San-Miguel JF, Rodriguez-Otero P, Martín-Sánchez E, Paiva B; The Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) Cooperative Group. Tamariz-Amador LE, et al. Among authors: zabaleta a. Blood Cancer J. 2021 Dec 14;11(12):202. doi: 10.1038/s41408-021-00594-1. Blood Cancer J. 2021. PMID: 34907159 Free PMC article.
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.
Oliver-Caldes A, Español-Rego M, Zabaleta A, González-Calle V, Navarro-Velázquez S, Inogés S, de Cerio AL, Cabañas V, López-Muñoz N, Rodríguez-Otero P, Reguera JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosiñol L, Cid J, Tovar N, Sáez-Peñataro J, López-Parra M, Olesti E, Guillén E, Varea S, Rodríguez-Lobato LG, Battram AM, González MS, Sánchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prósper F, Juan M, Martínez-López J, Moraleda JM, Mateos MV, Urbano-Ispizua Á, Paiva B, Pascal M, Fernández de Larrea C. Oliver-Caldes A, et al. Among authors: zabaleta a. Clin Cancer Res. 2024 May 15;30(10):2085-2096. doi: 10.1158/1078-0432.CCR-23-3759. Clin Cancer Res. 2024. PMID: 38466644
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD. Seckinger A, et al. Among authors: zabaleta a. Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2. Cancer Cell. 2017. PMID: 28262554 Free article.
60 results